Breast Care Center
Protocol for Management of Neutropenic Fever
Definitions
| Fever: | oral temp of | ≥38.3 C (101F) – single spike |
| Or | ||
| ≥ 38.0 (100.4F) for at least one hour | ||
| Neutropenia: | neutrophil count | <500/mm3 |
Signs and Symptoms
- History:
- Onset, duration and pattern of fever
- Date of last course of chemotherapy and drugs administered
- Associated complaints – stiff neck, rash, cuts or open areas on skin, port-a-cath redness or swelling, earache, sore throat, cold symptoms, cough, nausea/vomiting, abdominal pain, diarrhea, night sweats, chilling, confusion and urinary symptoms.
- Physical:
- Warm or flushed skin, shivering or chills, sweating, tachycardia, tachypnea, hypotension, appearance of port site, rash, skin exam. Include mouth, throat, lung and abdominal exam.
Evaluations
- CBC, with differential
- Blood cultures – peripheral and central, aerobic and anaerobic – if indicated
- Other tests, as indicated by the history or physical
Treatment Guidelines
- NP – consult with physician for all cases of neutropenia fever
- Evaluate High vs. Low Risk
- Low Risk Complications
- Neutropenia expected to last less than 7 to 10 days
- Absence of underlying conditions e.g. hypotension, pulmonary compromise, vomiting, significant mucositis, cognitive changes, other serious chronic diseases.
- High Risk of Complications
- Expected prolonged neutropenia
- Presence of underlying conditions as noted above
- Initial Choice of Antibiotics
- Low Risk – low risk patients who are reliable and have good psychosocial support should be treated on an outpatient basis
- Oral ciprofloxacin 500 mg PO every 8 hours for 5-7 days and Augmentin 500 mg PO every 8 hrs for 5 - 7 days.
- For patient allergic to penicillin, Clindamycin 300 mg PO every 6 hours for 5-7 days.
- Acetaminophen 650-1000 mg every 4 hours as needed.
- Daily phone call with patient until afebrile > 24 hours and symptoms resolving.
- High Risk
- i. Physician referral for hospital admission
From:
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Fever and Neutropenia. Version 1.2005 Myeloid Growth Factors in Cancer Treatment. Version 2.2005.
- Telephone Conversation, January 2006. Alfred Lee, Infectious Diseases at Baylor College of Medicine.
- Frefield, A, Marchigiani, D, Walsh, T, et al. A double-blind comparison of empirical or oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341: 305-311.
Reviewed: 7/1/04, 1/25/06
Powel Brown, M.D.
Jenny Chang, M.D.
Richard Elledge, M.D.
Mamta Kalidas, M.D.
Rush Lynch, M.D.
Kent Osborne, M
Suzanne Perez, RN, BSN
Mari Rude, RN, ANP
